Journal of Hepatocellular Carcinoma最新文献

{"title":"A Comparative Study of Five Large Language Models' Response for Liver Cancer Comprehensive Treatment.","authors":"Deyuan Zhong, Yuxin Liang, Hong-Tao Yan, Xinpei Chen, Qinyan Yang, Shuoshuo Ma, Yuhao Su, YaHui Chen, Xiaolun Huang, Ming Wang","doi":"10.2147/JHC.S531642","DOIUrl":"10.2147/JHC.S531642","url":null,"abstract":"<p><strong>Introduction: </strong>Large language models (LLMs) are increasingly used in healthcare, yet their reliability in specialized clinical fields remains uncertain. Liver cancer, as a complex and high-burden disease, poses unique challenges for AI-based tools. This study aimed to evaluate the comprehensibility and clinical applicability of five mainstream LLMs in addressing liver cancer-related clinical questions.</p><p><strong>Methods: </strong>We developed 90 standardized questions covering multiple aspects of liver cancer management. Five LLMs-GPT-4, Gemini, Copilot, Kimi, and Ernie Bot-were evaluated in a blinded fashion by three independent hepatobiliary experts. Responses were scored using predefined criteria for comprehensibility and clinical applicability. Overall group comparisons were conducted using the Fisher-Freeman-Halton test (for categorical data) and the Kruskal-Wallis test (for ordinal scores), followed by Dunn's post-hoc test or Fisher's exact test with Bonferroni correction. Inter-rater reliability was assessed using Fleiss' kappa.</p><p><strong>Results: </strong>Kimi and GPT-4 achieved the highest proportions of fully applicable responses (68% and 62%, respectively), while Ernie Bot and Copilot showed the lowest. Comprehensibility was generally high, with Kimi and Ernie Bot scoring over 98%. However, none of the LLMs consistently provided guideline-concordant answers to all questions. Performance on professional-level questions was significantly lower than on common-sense ones, highlighting deficiencies in complex clinical reasoning.</p><p><strong>Conclusion: </strong>LLMs demonstrate varied performance in liver cancer-related queries. While GPT-4 and Kimi show promise in clinical applicability, limitations in accuracy and consistency-particularly for complex medical decisions-underscore the need for domain-specific optimization before clinical integration.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1861-1871"},"PeriodicalIF":3.4,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of the Multi-Level Comprehensive Collateral Artery Embolism Sequential Hepatic Arterial Infusion Chemotherapy, Combined with TKI and ICI, for Unresectable Huge Hepatocellular Carcinoma (>10cm): A Propensity Score Matching Cohort Study.","authors":"Hao-Yang Tan, Shuang-Quan Liu, Yan-Han Liu, Jiu-Ling Zheng, Hua-Guo Feng","doi":"10.2147/JHC.S546588","DOIUrl":"10.2147/JHC.S546588","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective study was conducted to evaluate the effectiveness and safety of a new combination therapy of the multi-level comprehensive collateral artery embolism (CAE) sequential hepatic arterial infusion chemotherapy (HAIC), tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) for unresectable huge hepatocellular carcinoma (>10cm) patients.</p><p><strong>Methods: </strong>A propensity score-matching (PSM) cohort study was conducted. The initial tumor response, treatment-related adverse events, and survival outcomes were compared. The Forestplot package was used to visualize and interpret forest plots of overall survival subgroup analyses. Univariate and multivariate analyses were conducted to explore the risk factors of overall survival.</p><p><strong>Results: </strong>Thirty-one pairs of patients were evaluated after PSM. There were statistically significant differences in the initial tumor response and objective response rate (ORR) between the two groups (74.2% vs 48.4%, P=0.037). Compared with the \"HAIC\" group, the incidence of abdominal pain was higher in the \"CAE+HAIC\" group (71.0% vs 41.9%, P=0.021). The OS and progression-free survival (PFS) of the \"CAE+HAIC\" group were longer than those of the \"HAIC\" group (OS: HR=0.439, 95% CI: 0.199-0.970, P=0.042; PFS: HR=0.475; 95% CI: 0.252-0.895; P=0.021). The CAE (HR=0.403, 95% CI: 0.213-0.762; P=0.005), prealbumin levels <170 mg/L (HR=2.195, 95% CI: 1.226-3.929; P=0.008), and lactic dehydrogenase levels >245 U/L (HR=2.136, 95% CI: 1.215-3.757; P=0.008) were independent risk factors of OS.</p><p><strong>Conclusions: </strong>The multi-level comprehensive CAE sequential HAIC, combined with TKI and ICI, can improve tumor response and prolong survival time in unresectable huge HCC patients while remaining safe and tolerable.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1821-1834"},"PeriodicalIF":3.4,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12374706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Clinical-Imaging Nomogram for Predicting Early Recurrence in Patients with Solitary Hepatocellular Carcinoma After Postoperative Adjuvant TACE.","authors":"Jiachen Liu, Xiurong Ding, Yanyan Zhang, Hongjun Li","doi":"10.2147/JHC.S544127","DOIUrl":"10.2147/JHC.S544127","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to identify independent predictors of early recurrence (ER) and to establish a clinically applicable, individualized nomogram for patients with solitary hepatocellular carcinoma (HCC) who underwent postoperative adjuvant transarterial chemoembolization (PA-TACE).</p><p><strong>Methods: </strong>A total of 165 patients with solitary HCC treated with PA-TACE between January 2018 and December 2022 were retrospectively analyzed. Among these patients, 71 experienced ER, while 94 remained recurrence-free for over 24 months. Independent prognostic variables were identified through univariate and multivariate Cox regression analyses. These factors were integrated into a nomogram model, and its performance was evaluated using internal validation and calibration curves.</p><p><strong>Results: </strong>Multivariate analysis revealed that AFP-L3% >10% (<i>p</i> = 0.009), presence of satellite lesions (<i>p</i> = 0.026), GLR >20 (<i>p</i> = 0.020), microvascular invasion (MVI) (<i>p</i> = 0.008), and Ki-67 expression >50% (<i>p</i> < 0.001) were independently associated with ER. These five variables were used to establish the nomogram, which had a C-index of 0.763 (95% CI: 0.736-0.870).</p><p><strong>Conclusion: </strong>A nomogram incorporating AFP-L3, satellite lesions, GLR, MVI, and Ki-67 for predicting ER in patients with solitary HCC following PA-TACE was developed and validated. This model exhibits high predictive accuracy and provides a valuable tool for identifying patients who may benefit from PA-TACE.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1835-1847"},"PeriodicalIF":3.4,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12374716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Quadruple Conversion Therapy: Converting Initially Unresectable Hepatocellular Carcinoma to Resectable with pTAE-HAIC, Tyrosine Kinase Inhibitors, and Anti-PD-1 Antibodies.","authors":"Jing Xiao, Qingdong Li, Wentao Zheng, Kaiyou Liao, Qianwen Yu, Rongzhong Huang, Rong Zhou","doi":"10.2147/JHC.S523755","DOIUrl":"10.2147/JHC.S523755","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to evaluate the potential of partial transcatheter arterial embolization (pTAE)-hepatic artery infusion chemotherapy (HAIC) in combination with tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies for downstaging and subsequent resection in patients with initially unresectable hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>Patients with unresectable HCC who underwent initial treatment with a combination of pTAE, HAIC, TKIs, and an anti-PD-1 antibody were studied. The tumour response and potential for resection were assessed through imaging every month (±1 week) using RECIST v1.1.</p><p><strong>Results: </strong>Among 17 patients (27.4%) who achieved R0 resection, the median time from quadruple therapy initiation to surgery was 89 days (range: 69-255). The cohort comprised 13 males and 4 females, with a median age of 51 years (range: 18-70). Twelve patients had BCLC stage C disease, including 11 with major vascular invasion (Vp2, Vp3, Vv2, Vv3, Vv1) and 3 with concurrent portal and hepatic venous invasion (Vp2/Vv2, Vp3/Vv2, Vp3/Vv3). Five patients had BCLC stage B HCC. The median diameter of the largest liver nodule was 11.5 cm (range: 3.9-18.8), with 10 patients presenting multiple lesions. Preoperatively, 17 patients underwent 43 cycles of pTAE-HAIC (median: 2, range: 1-5). Based on RECIST v1.1, 13 patients achieved partial response (PR), and 4 had stable disease (SD). With a median follow-up of 17.8 months (range: 12.2-38.3), the 12-month overall survival post-hepatectomy was 100%, and the median progression-free survival (PFS) was 14.5 months (range: 1.5-31.8). Tumor recurrence within 12 months occurred in 5 patients, with 4 achieving disease control after additional treatment.</p><p><strong>Conclusion: </strong>Quadruple therapy, consisting of pTAE-HAIC combined with TKIs and anti-PD-1 antibodies, represents a feasible conversion strategy for patients with unresectable HCC to achieve successful resection and potential long-term survival.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1807-1819"},"PeriodicalIF":3.4,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144883006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transarterial Chemoembolization Following Curative Resection May Not Improve Survival for Hepatitis B Virus Associated Intrahepatic Cholangiocarcinoma: Propensity Score Weighting Analysis.","authors":"Guofang Liu, Wendi Liu, Fuping Zhou, Jinrong Qiu, Xijing Yang, Xiaoxia Kou, Lingling Guo, Yongmei Ding, Huiying Liu, Huabang Zhou","doi":"10.2147/JHC.S518418","DOIUrl":"10.2147/JHC.S518418","url":null,"abstract":"<p><strong>Background: </strong>For hepatocellular carcinoma (HCC), adjuvant transarterial chemoembolization (TACE) shows an advantageous response and prognosis in recurrent patients after resection. In consideration of similar pathogenesis and clinicopathological characteristics, studies should be conducted to ascertain whether hepatitis B virus (HBV)-associated intrahepatic cholangiocarcinoma (ICC) can be successfully treated by the methods used to treat HCC. The role of adjuvant TACE following liver resection for HBV-associated ICC remains controversial. This study aims to evaluate the efficacy of adjuvant TACE on recurrence and survival after liver resection, both before and after propensity score weighting (PSW) analysis.</p><p><strong>Materials and methods: </strong>A total of 356 patients were categorized into two groups: i) 77 patients who received adjuvant TACE, and ii) 279 patients who underwent R0 resection alone. Staging was conducted according to the 8th edition of the American Joint Committee on Cancer (AJCC) Tumor-Node-Metastasis (TNM) staging system. Univariate and multivariate analyses were utilized to assess independent prognostic factors. Recurrence-free survival (RFS) and overall survival (OS) rates were compared using the Kaplan-Meier method.</p><p><strong>Results: </strong>Among the 356 enrolled patients, 77 received adjuvant TACE. The median follow-up period was 45.3 months. Adjuvant TACE did not significantly affect OS (P=0.629) before or after PSW. Subgroup analyses indicated that TACE was not associated with OS across different TNM stages. After propensity score weighting, Cox regression model indicated significantly increased recurrence risk with TACE (HR=1.53, 95% CI: 1.02-2.28; P=0.0071). Stage-specific risks were visually summarized in Supplementary Figure 1. Additionally, TACE did not significantly impact RFS in TNM stage I (P=0.1720) and stage II (P=0.7905) subgroups. Conversely, TACE was positively associated with increased recurrence risk in TNM stage III (P=0.0014) and stage IV (P=0.0051) patients.</p><p><strong>Conclusion: </strong>These findings suggest that adjuvant TACE following radical surgery does not prolong OS for patients with HBV-associated ICC. Furthermore, adjuvant TACE was associated with increased recurrence risk in TNM Stage III and IV subgroups, though this observation requires further validation due to sample size limitations in advanced stages.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1781-1793"},"PeriodicalIF":3.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TACE Sequential to Radiofrequency Ablation versus RFA Alone in Hepatocellular Carcinoma Within Milan Criteria.","authors":"Huzheng Yan, Chenghao Zhao, Mingming Liu, Huan Liu, Luwen Mu, Zhanwang Xiang, Mingsheng Huang","doi":"10.2147/JHC.S534039","DOIUrl":"10.2147/JHC.S534039","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to compare the efficacy and safety of transarterial chemoembolization followed by radiofrequency ablation (cTACE-RFA) versus RFA alone in patients with early-stage hepatocellular carcinoma (HCC) within the Milan criteria.</p><p><strong>Methods: </strong>A retrospective analysis included 343 patients with Milan criteria-compliant HCC. After 1:1 propensity score matching (PSM), 93 patients underwent cTACE-RFA, and 93 received RFA alone. Primary endpoints were overall survival (OS) and local progression-free survival (LPFS).</p><p><strong>Results: </strong>The TACE-RFA group demonstrated significantly superior 1-, 3-, and 5-year LPFS rates (84.9%, 58.1%, 36.6%) compared to the RFA group (75.3%, 44.1%, 16.1%; HR=0.54, 95% CI: 0.37-0.79, P=0.001). However, no significant 1-, 3-, and 5-year OS difference (HR = 1.06, 95% CI: 0.61-1.83, p = 0.843) was observed between cTACE-RFA (95.7%, 80.6%, 59.1%) and RFA alone group (96.8%, 78.5%, 61.3%). Subgroup analyses revealed significant OS improvements with cTACE-RFA in tumor with high-risk locations (HR = 0.38; 95% CI: 0.17-0.85, p = 0.018) and diameter 3-5 cm: (HR = 0.28; 95% CI: 0.12-0.64, p = 0.003). cTACE-RFA group also was observed significant LPFS improvements for tumors in high-risk locations (HR=0.48, 95% CI: 0.30-0.77, p=0.002) or 3-5 cm in size (HR=0.25, 95% CI: 0.15-0.41, p<0.001). Complication rates were comparable, with no procedure-related mortality and similar severe adverse event incidences (P=0.516).</p><p><strong>Conclusion: </strong>cTACE-RFA significantly prolongs LPFS compared to RFA alone in early HCC, particularly for tumors >3 cm or in high-risk locations, without increasing major complications.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1795-1805"},"PeriodicalIF":3.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whether Adjuvant TACE Plus TKI Therapy is More Effective Than TACE Alone in HCC Patients at High Risks of Recurrence Following Radical Hepatectomy.","authors":"Yaohua Li, Kai Wang, Huixia Qin, Shengjun Huo, Kaiwen Jiang, Jing Xia, Jing Gu, Houxiang Ya, Liya Suo, Dejie Wang, Xiaowang Huang, Shuqun Li","doi":"10.2147/JHC.S534143","DOIUrl":"10.2147/JHC.S534143","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the efficacy and safety of postoperative adjuvant therapy with transarterial chemoembolization (TACE) plus tyrosine kinase inhibitor (TKI) (TPT) versus TACE alone in hepatocellular carcinoma (HCC) patients at high risks of recurrence after radical hepatectomy.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed 264 HCC patients who underwent radical hepatectomy (R0 resection) between August 2016 and August 2023. To mitigate selection bias, propensity score matching (PSM) was employed. The primary endpoints were recurrence-free survival (RFS) and overall survival (OS), analyzed using Kaplan-Meier curves and Log rank tests. Treatment-related adverse events (TRAEs) were graded according to CTCAE v4.0. Prognostic factors were evaluated via Cox proportional hazards regression.</p><p><strong>Results: </strong>Before PSM, the cohort comprised 141 patients receiving TPT and 123 patients treated with TACE alone. After PSM, 81 well-balanced patients were selected per group (all p > 0.05). The TPT group exhibited significantly prolonged median recurrence-free survival (mRFS: 37.1 vs 27.7 months; p < 0.05) and median overall survival (mOS: 41.3 vs 38.3 months; p < 0.05) compared to the TACE alone group. The 1-, 2-, and 3-year RFS rates in the TPT group were 95.1%, 67.9%, and 48.1%, respectively, significantly higher than those in the TACE alone group (76.5%, 55.6%, and 40.7%; all p < 0.05). Similarly, the corresponding OS rates were 95.1%, 75.3%, and 54.3% (TPT) versus 81.5%, 66.7%, and 53.1% (TACE alone; all p < 0.05). Multivariable Cox regression analyses confirmed TPT as an independent protective factor for both RFS and OS. No significant increase in treatment-related adverse events (TRAEs) was observed with the TPT regimen compared to TACE alone. The overall TRAE rate was 51.8% in the TPT group, with grade ≥3 events occurring in 14.8% of patients, indicating an acceptable safety profile.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1767-1780"},"PeriodicalIF":3.4,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12356218/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Radiomics-Based Model for Recurrence-Free Survival After Curative Resection in Patients with Hepatocellular Carcinoma.","authors":"Jinfeng Cui, Zhongkun Lin, Xiaojuan Huang, Shasha Wang, Jing Guo, Jialin Song, Siyi Zhang, Jing Lv, Wensheng Qiu","doi":"10.2147/JHC.S535492","DOIUrl":"10.2147/JHC.S535492","url":null,"abstract":"<p><strong>Background: </strong>Postoperative recurrence after curative resection is a major concern in the management of hepatocellular carcinoma (HCC). This study aimed to develop a radiomics-based model for predicting recurrence-free survival (RFS) after curative resection.</p><p><strong>Methods: </strong>We retrospectively included 184 patients with early-stage HCC who underwent curative resection. The patients were randomized into training and validation sets in a 7:3 ratio. Radiomics features of the tumors on CT images were extracted to construct the Rad-score. We incorporated the Rad-score, clinical characteristics and biochemical parameters into univariate and multivariate analyses to construct a COX proportional hazards model. A radiomics-based nomogram model for predicting recurrence risk was developed by integrating multiple factors that affect recurrence. Calibration curve was used to assess the predictive performance of the model.</p><p><strong>Results: </strong>Rad-score was constructed using 15 radiomic features. The results of multivariate analyses showed that Rad-score, lactate dehydrogenase (LDH) and alpha-fetoprotein (AFP) were independent predictors of RFS. They categorized patients into different recurrence risk groups, and RFS was significantly prolonged in patients in the low-risk group in the training (p<0.001) and validation sets (p<0.001). The Rad-score based composite prediction model showed good predictive performance with AUC of 0.765 and 0.920 for predicting 3 years RFS in the training and validation sets, respectively. The calibration curves indicated that the nomogram model had a favorable predictive performance.</p><p><strong>Conclusion: </strong>This postoperative predictive model allows for better screening of patients at a high risk of recurrence and is a valuable instrument to guide clinicians in clinical treatment decisions.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1755-1766"},"PeriodicalIF":3.4,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12338097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144821526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Value of IDEAL-IQ and DWI Imaging Biomarkers for P53 Mutations in Hepatocellular Carcinoma.","authors":"Dongdong Wang, Huijia Yin, Xiaoming Li, Shuwei Zhou, Yuan-Cheng Wang","doi":"10.2147/JHC.S524533","DOIUrl":"10.2147/JHC.S524533","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the application of imaging biomarkers, including R2*, Fat Fraction (FF) and apparent diffusion coefficient (ADC) values, obtained through Iterative Decomposition of water and fat with Echo Asymmetry and Least-squares estimation for Imaging Quantification (IDEAL-IQ) and DWI techniques, in differentiating P53-mutated and non-mutated HCC.</p><p><strong>Patients and methods: </strong>This retrospective study included patients with pathologically confirmed HCC between January 2019 and July 2024. HCC were divided into P53-mutated group and non-mutated group by immunostaining. Preoperative R2*, FF, and ADC values derived from IDEAL-IQ and DWI were compared between the two groups, as well as different histological grades. Receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic performance of each MRI parameter for detecting P53 mutations in HCC, with area under the curve (AUC) compared by Delong's test.</p><p><strong>Results: </strong>Compared to the non-mutated group, the P53-mutated group (n = 31) showed significantly higher R2* values (34.821 ± 9.980 vs 23.713 ± 5.586, P < 0.001) and lower ADC values (0.760 ± 0.142 vs 0.855 ± 0.130, P = 0.002), while FF values showed no significant difference (P = 0.646). R2*, ADC, and the combined model (R2* + ADC) revealed AUCs of 0.849, 0.726, and 0.856, respectively, with the combined model demonstrating the highest sensitivity and specificity. Additionally, high-grade HCC showed significantly lower ADC values compared to lower-grade tumors (P < 0.001).</p><p><strong>Conclusion: </strong>R2* and ADC exhibited significant features in P53-mutated HCC, suggesting their potential as non-invasive biomarkers for predicting P53 mutation status and guiding clinical management. The combined use of R2* and ADC may further enhance diagnostic accuracy.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1743-1753"},"PeriodicalIF":3.4,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144821527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triphasic CT Radiomics Model for Preoperative Prediction of Hepatocellular Carcinoma Pathological Grading.","authors":"Haibo Huang, Xianpan Pan, Yingdan Zhang, Jie Yang, Lei Chen, Qinping Zhao, Lifeng Huang, Wei Lu, Yaohong Deng, Yingying Huang, Ke Ding","doi":"10.2147/JHC.S527056","DOIUrl":"10.2147/JHC.S527056","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to develop and validate a triphasic CT-based radiomics model for the synchronous prediction of multiple critical pathological markers in hepatocellular carcinoma (HCC).</p><p><strong>Materials and methods: </strong>This retrospective study analyzed 174 patients with 187 hepatocellular carcinoma (HCC) lesions. Radiomic features (n = 2264) were extracted from arterial phase (AP), venous phase (VP), and delayed phase (DP) CT images. Key features were selected using minimum redundancy maximum relevance (mRMR), SelectKBest, and least absolute shrinkage and selection operator (LASSO) algorithms. Logistic regression and support vector machine (SVM) classifiers were employed to develop individual phase-specific models and a triphasic fusion model. Model performance was evaluated through the area under the curve (AUC), sensitivity, specificity, decision curve analysis, and other metrics.</p><p><strong>Results: </strong>The triphasic fusion model demonstrated superior performance. In the testing 1 dataset, the triphasic fusion model achieved AUCs of 0.890 (95% CI: 0.741-1), 0.895 (95% CI: 0.781-1) and 0.829 (95% CI: 0.675-0.984) for Edmondson-Steiner (Ed) grading, Microvascular invasion (MVI) grading, and Satellite nodule (SN) grading, respectively. In the testing 2 (validation) dataset, the triphasic fusion model achieved AUCs of 0.836 (95% CI: 0.739-0.934), 0.871 (95% CI: 0.748-0.993) and 0.810 (95% CI: 0.656-0.963) for Ed, MVI, and SN grading, respectively. The performance of the fusion model was better than that of the single-phase models.</p><p><strong>Conclusion: </strong>The triphasic CT radiomics model provides a noninvasive tool for preoperative prediction of HCC pathological grading (Ed, MVI, SN), enhancing diagnostic accuracy for clinical decision-making and prognostic evaluation.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1725-1742"},"PeriodicalIF":3.4,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144821528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}